58 related articles for article (PubMed ID: 2986094)
1. Cyclosporine-associated lymphoproliferation, despite controlled cyclosporine blood concentrations, in a renal allograft recipient.
Dossetor JB; Kovithavongs T; Salkie M; Preiksaitis J
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():1021-6. PubMed ID: 2986094
[TBL] [Abstract][Full Text] [Related]
2. Posttransplantation cyclosporine-induced lymphoproliferative disorders: clinical and radiologic manifestations.
Harris KM; Schwartz ML; Slasky BS; Nalesnik M; Makowka L
Radiology; 1987 Mar; 162(3):697-700. PubMed ID: 3544033
[TBL] [Abstract][Full Text] [Related]
3. Does renal failure induce a decrease in cyclosporine blood concentrations?
Burnier M; Aebischer P; Wauters JP; Schelling JL
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():1002-5. PubMed ID: 3887367
[TBL] [Abstract][Full Text] [Related]
4. The impact of cyclosporine therapy on the occurrence of infection in the renal transplant recipient.
Tolkoff-Rubin NE; Rubin RH
Transplant Proc; 1986 Apr; 18(2 Suppl 1):168-76. PubMed ID: 3008389
[No Abstract] [Full Text] [Related]
5. Prevention of nephrotoxic cyclosporine peak concentrations by daily drug division in 3 equal oral portions.
Zazgornik J; Schindler J; Balcke P; Kopsa H; Gremmel F; Derfler K; Kretschmer G; Mühlbacher F; Piza F
Int J Clin Pharmacol Ther Toxicol; 1987 Apr; 25(4):197-200. PubMed ID: 3294613
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies.
Rosano TG; Pell MA; Freed BM; Dybas MT; Lempert N
Transplant Proc; 1988 Apr; 20(2 Suppl 2):330-8. PubMed ID: 3284076
[No Abstract] [Full Text] [Related]
7. The free fraction of cyclosporine in plasma: clinical findings with a new method.
Lindholm A; Henricsson S; Gang P
Transplant Proc; 1988 Apr; 20(2 Suppl 2):377-81. PubMed ID: 2834841
[No Abstract] [Full Text] [Related]
8. Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders.
Gupta AK; Rocher LL; Schmaltz SP; Goldfarb MT; Brown MD; Ellis CN; Voorhees JJ
Arch Intern Med; 1991 Feb; 151(2):356-62. PubMed ID: 1992963
[TBL] [Abstract][Full Text] [Related]
9. [Post-transplantation lymphoproliferation in patients with intensive immunosuppression].
Vavrinová H; Viklický O; Lácha J; Housa D; Hosková L; Teplan V
Vnitr Lek; 2006 Jun; 52(6):645-8. PubMed ID: 16871771
[TBL] [Abstract][Full Text] [Related]
10. Acute myelogenous leukemia in a renal allograft recipient receiving cyclosporine therapy.
Butler J; Korb S; Light J
Transplantation; 1990 Apr; 49(4):813-5. PubMed ID: 2326877
[No Abstract] [Full Text] [Related]
11. Sequential analyses of the development of lymphoproliferative disorders in rats receiving cyclosporine.
Demetris AJ; Nalesnik MA; Kunz HW; Gill TJ; Shinozuka H
Transplantation; 1984 Sep; 38(3):239-46. PubMed ID: 6474554
[TBL] [Abstract][Full Text] [Related]
12. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients.
Lewis RM; Van Buren CT; Radovancevic B; Frazier OH; Janney RP; Powers PL; Golden DL; Giannakis JG; Macris MP; Kerman RH
J Heart Lung Transplant; 1991; 10(1 Pt 1):63-70. PubMed ID: 2007172
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine monitoring with polyclonal and specific monoclonal antibodies during episodes of renal allograft dysfunction.
Holt DW; Marsden JT; Johnston A; Taube DH
Transplant Proc; 1989 Feb; 21(1 Pt 2):1482-4. PubMed ID: 2652475
[No Abstract] [Full Text] [Related]
14. [Clinical renal transplantation: exfoliative urinary cytology in the evaluation of nephrotoxicity induced by cyclosporin therapy].
Stella F; Alfani D; Renna Molajoni E; Rossi M; Rossi Lemeni A; Stella C; Di Tondo U; Troccoli R; Cortesini R
Quad Sclavo Diagn; 1984 Sep; 20(3):295-303. PubMed ID: 6397762
[TBL] [Abstract][Full Text] [Related]
15. Treatment of moderate heart allograft rejection with cyclosporine.
Radovancevic B; Frazier OH
J Heart Transplant; 1986; 5(4):307-11. PubMed ID: 3114444
[TBL] [Abstract][Full Text] [Related]
16. Retreatment by antithymocyte globulin for second kidney transplantation: efficacy, tolerance and safety.
Rodríguez-Reimundes E; Buron F; Chauvet C; Daoud S; Thaunat O; Brunet M; Badet L; Morelon E
Transpl Immunol; 2013 Jan; 28(1):6-8. PubMed ID: 23220146
[TBL] [Abstract][Full Text] [Related]
17. The impact of cyclosporine on the practice of renal transplantation.
Kahan BD
Transplant Proc; 1989 Jun; 21(3 Suppl 1):63-9. PubMed ID: 2545019
[No Abstract] [Full Text] [Related]
18. Effects of cyclosporine on renal function following orthotopic heart transplantation.
McKenzie N; Keown P; Stiller C; Kostuk W; Campbell C; Keith F
J Heart Transplant; 1985; 4(4):400-3. PubMed ID: 3916514
[TBL] [Abstract][Full Text] [Related]
19. Acute renal failure after heart transplantation and cyclosporine therapy.
McGiffin DC; Kirklin JK; Naftel DC
J Heart Transplant; 1985; 4(4):396-9. PubMed ID: 3916513
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of cyclosporine blood levels with polyclonal and monoclonal assays during episodes of renal graft dysfunction.
Martinez L; Foradori A; Vaccarezza A; Martinez P; Rodriguez L
Transplant Proc; 1989 Feb; 21(1 Pt 2):1490-1. PubMed ID: 2652479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
